AMENDMENT OF THE CLAIMS

Please amend the claims as follows. This listing of claims will replace all prior versions, and listings, of claims in the application.

- 1. (Currently amended) A method to reduce recruitment of <u>IDO+ dendritic cells</u> antigen presenting cells (APCs) that inhibit T-cell proliferation to <u>at least one of a tumor or a tumor-draining lymph node a particular site</u> in a subject comprising administering a composition comprising an antibody to CCR6 to the subject to reduce recruitment of the <u>IDO+ dendritic cells</u> to the at least one of a tumor or a tumor-draining lymph node, wherein the <u>IDO+ dendritic cells</u> express CCR6 and elevated levels of indoleamine 2,3-dioxygenase (IDO), and tumor cells of the at least one of a tumor or a tumor draining lymph node express MIP-3α IDO+ APCs or their precursors to the site, wherein the site is determined to comprise recruitment of IDO+ APCs and wherein IDO+ APCs or their precursors are cells that express elevated levels of indoleamine 2,3-dioxygenase (IDO).
- 2. (Canceled)
- 3. (Original) The method of claim 1, wherein the subject is human.
- 4. (Currently amended) The method of claim 1, wherein the <u>CCR6</u> antibody eomposition comprises a compound that blocks the interaction between the <u>CCR6</u> expressed by the IDO+ dendritic cells and the MIP-3α expressed by tumor cells of the at least one of a tumor or a tumor draining lymph node a biological signal present at the site of APC recruitment and a protein expressed on the surface of the IDO+ antigen-presenting cells (APCs) or their precursors.
- 5. (Currently amended) The method of claim [[4]] $\underline{1}$, wherein the biological signal present at the site of APC recruitment comprises mip 3α further comprising the step of determining that IDO+ dendritic cells are recruited to the at the least one of a tumor or a tumor-draining lymph node.

Appln. Serial No. 10/660,131 Page 3 of 7

6. (Currently amended) The method of claim 1 [[4]], wherein the MIP-3α mediates recruitment of the IDO+ dendritic cells to the at least one of a tumor or a tumor draining lymph node protein expressed on the surface of the IDO+ antigen presenting cells (APCs) or their precursors comprises a chemokine receptor.

Claims 7-48 (Canceled)